Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.70217
Abstract: This study aimed to evaluate the efficacy and safety of atezolizumab combined with bevacizumab (Atez/Bev) compared to lenvatinib (LEN) as first‐line systemic therapy for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma… read more here.
Keywords: atezolizumab; stage hepatocellular; exceeding seven; hepatocellular carcinoma ... See more keywords